Full history for every metric is available with a Kvantra account
Paragon 28, Inc. (FNA)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 106 | 111 | 147 | 181 | 216 | 256 | 256 |
| Operating profit | $m | -41 | -39 | |||||
| Net profit | $m | 3 | 3 | -14 | -67 | -58 | -55 | -52 |
| EPS reported | $ | -0.66 | -0.63 | |||||
| Operating cashflow per share | $ | -0.33 | -0.33 | |||||
| Capex per share | $ | 0.20 | 0.20 | |||||
| FCF per share | $ | -0.53 | -0.53 | |||||
| Free cash flow | $m | -44 | -44 | |||||
| Net debt | $m | 76 | 76 | |||||
| Book value equity | $m | 131 | 131 | |||||
| Book value per share | $ | 1.57 | 1.57 | |||||
| Number of shares | m | 83.31 | 83.31 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 6.59 | 8.41 | |||||
| P/S LTM | x | 3.36 | 4.29 | |||||
| P/FCF LTM | x | -19.52 | -24.92 | |||||
| EV/EBITDA LTM | x | -40.03 | -50.20 | |||||
| EV/Sales LTM | x | 3.66 | 4.59 | |||||
| Earnings Yield LTM | % | -6.35% | -5.01% | |||||
| FCF Yield | % | -5.12% | -4.01% | |||||
| Quality | ||||||||
| ROE | % | -41.84% | -35.44% | |||||
| ROIC | % | -16.77% | -16.77% | |||||
| Operating margin | % | -15.92% | -15.92% | |||||
| Gross margin | % | 74.75% | 74.75% | |||||
| FCF/Sales | % | -17.21% | -17.21% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +18.39% | +18.39% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.40 | -0.40 | |||||
| Net Debt/EBITDA | x | -3.25 | -3.25 | |||||
| EBIT/Net interest | x | -3.54 | -3.54 | |||||
| Net debt/market cap | % | 8.84% | 6.93% | |||||
| Net debt/Equity | x | 0.58 | 0.58 | |||||
| Gross debt/equity | x | 0.85 | 0.85 | |||||
Company overview
Paragon 28, Inc. is a medical device company specializing in the development, manufacturing, and global distribution of advanced surgical systems tailored for foot and ankle procedures. Its comprehensive product portfolio encompasses a wide array of solutions: Plating Systems: This includes the Gorilla plating series, offering specific solutions for Lisfranc injuries, Lapidus procedures, lateral column corrections, calcaneus slides, and naviculocuneiform (NC) fusions. Complementary products like Baby Gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates, as well as Silverback plating systems, are also available. Precision Guidance Technology: The company provides sophisticated guidance systems to enhance accuracy in various operations, such as fusion procedures for bunion deformities, first tarsometatarsal arthrodesis, metatarsal osteotomy for bunion correction, medial column beaming for Charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. Screw Systems: Paragon 28 offers robust screw systems, including the Monster, Mini Monster, and Joust beaming lines, which are critical for applications like bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, and fracture repair. Joint Replacement Solutions: Their offerings extend to total ankle replacement with the APEX 3D systems, alongside total talus spacers designed to replace the talus bone that links the leg and foot. Bunion/Hallux Valgus Correction Systems: Specifically for bunion management, the company provides nail systems such as the Phantom intramedullary nail systems, targeting severe hallux valgus cases. Orthobiologics: A substantial part of their product line comprises various orthobiologics, including bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix. They also feature PRESERVE bone graft systems for homologous applications. Ancillary Products: The company further supplies soft tissue fixation systems, titanium sprayed polyetheretherketone (PEEK) implants, nitinol staple systems, stabilization solutions, and specialized curved instruments. Paragon 28 distributes its products to hospitals and ambulatory surgery centers through an established network of both direct sales representatives and stocking distributors. Founded in 2010, the company maintains its corporate headquarters in Englewood, Colorado.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Paragon 28, Inc. (FNA)
Paragon 28, Inc. is a medical device company specializing in the development, manufacturing, and global distribution of advanced surgical systems tailored for foot and ankle procedures. Its comprehensive product portfolio encompasses a wide array of solutions: Plating Systems: This includes the Gorilla plating series, offering specific solutions for Lisfranc injuries, Lapidus procedures, lateral column corrections, calcaneus slides, and naviculocuneiform (NC) fusions. Complementary products like Baby Gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates, as well as Silverback plating systems, are also available. Precision Guidance Technology: The company provides sophisticated guidance systems to enhance accuracy in various operations, such as fusion procedures for bunion deformities, first tarsometatarsal arthrodesis, metatarsal osteotomy for bunion correction, medial column beaming for Charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. Screw Systems: Paragon 28 offers robust screw systems, including the Monster, Mini Monster, and Joust beaming lines, which are critical for applications like bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, and fracture repair. Joint Replacement Solutions: Their offerings extend to total ankle replacement with the APEX 3D systems, alongside total talus spacers designed to replace the talus bone that links the leg and foot. Bunion/Hallux Valgus Correction Systems: Specifically for bunion management, the company provides nail systems such as the Phantom intramedullary nail systems, targeting severe hallux valgus cases. Orthobiologics: A substantial part of their product line comprises various orthobiologics, including bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix. They also feature PRESERVE bone graft systems for homologous applications. Ancillary Products: The company further supplies soft tissue fixation systems, titanium sprayed polyetheretherketone (PEEK) implants, nitinol staple systems, stabilization solutions, and specialized curved instruments. Paragon 28 distributes its products to hospitals and ambulatory surgery centers through an established network of both direct sales representatives and stocking distributors. Founded in 2010, the company maintains its corporate headquarters in Englewood, Colorado.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free